01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity
Jérôme Devy, Farid Ouchani, Christelle Oudot, Jean Jacques Helesbeux, Enguerran Vanquelef, Stéphanie Salesse, Fanja Rabenoelina, Siana Al-Khara, Isabelle Letinois, Olivier Duval, Laurent Martiny, Emmanuelle Charpentier
01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis
Danqing Xu, Ji Cao, Shijing Qian, Lin Li, Chunqi Hu, Qinjie Weng, Jianshu Lou, Difeng Zhu, Hong Zhu, Yongzhou Hu, Qiaojun He, Bo Yang
01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα
Min Gui, Da-Kuo Shi, Min Huang, Yu Zhao, Qi-Ming Sun, Jing Zhang, Qin Chen, Jian-Ming Feng, Chun-Hong Liu, Ming Li, Ying-Xia Li, MeiYu Geng, Jian Ding
01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells
Bo-Kyung Kim, Dong-Myung Kim, Kyung-Sook Chung, Song-Kyu Park, Shin-Jung Choi, Alexander Song, Kiho Lee, Chang-Woo Lee, Kyung-Bin Song, Gyoonhee Han, Julian Simon, Hwan Mook Kim, Misun Won
01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice
Jin-Bin Jia, Wen-Quan Wang, Hui-Chuan Sun, Liang Liu, Xiao-Dong Zhu, Ling-Qun Kong, Zong-Tao Chai, Wei Zhang, Ju-Bo Zhang, Hua-Xiang Xu, Zhao-Chong Zeng, Wei-Zhong Wu, Lu Wang, Zhao-You Tang
01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study
Raphaël Beck, Rozangela Curi Pedrosa, Nicolas Dejeans, Christophe Glorieux, Philippe Levêque, Bernard Gallez, Henryk Taper, Stéphane Eeckhoudt, Laurent Knoops, Pedro Buc Calderon, Julien Verrax
01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs
Pamela W. Lucas, Joanna M. Schmit, Quinn P. Peterson, Diana C. West, Danny C. Hsu, Chris J. Novotny, Levent Dirikolu, Mona I. Churchwell, Daniel R. Doerge, Laura D. Garrett, Paul J. Hergenrother, Timothy M. Fan
01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011
Open Access
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
Neeltje Steeghs, Ron H. J. Mathijssen, Judith A. M. Wessels, Anne-Joy de Graan, Tahar van der Straaten, Mariangela Mariani, Bernard Laffranchi, Silvia Comis, Maja J. A. de Jonge, Hans Gelderblom, Henk-Jan Guchelaar
01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer
Donald A. Richards, David Loesch, Svetislava J. Vukelja, Hillary Wu, William J. Hyman, Jeffery Nieves, Yunfei Wang, Simin Hu, Oluwatoyin O. Shonukan, Datchen F. Tai
01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors
Hanna K. Sanoff, Janine M. Davies, Christine Walko, William Irvin, Larry Buie, Kimberly Keller, Anastasia Ivanova, Wing-Keung Chiu, Bert H. O’Neil, Thomas E. Stinchcombe, E. Claire Dees
01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011
Open Access
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
Elena Soto, Ron J. Keizer, Iñaki F. Trocóniz, Alwin D. R. Huitema, Jos H. Beijnen, Jan H. M. Schellens, Jantien Wanders, Josep María Cendrós, Rosendo Obach, Concepción Peraire, Lena E. Friberg, Mats O. Karlsson
01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
Benoit You, Anthony Brade, Joao M. Magalhaes, Lillian L. Siu, Amit Oza, Sonya Lovell, Lisa Wang, David W. Hedley, Leonardo V. Nicacio, Eric X. Chen
01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Mark Andrew Dickson, Dana E. Rathkopf, Richard D. Carvajal, Steven Grant, John D. Roberts, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Robert A. Lefkowitz, Mithat Gonen, Lauren M. Cane, Heather J. Dials, Gary K. Schwartz
01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Jaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, Katalin Boer, Antoine Adenis, Pilar Escudero, Tae-You Kim, Gillian M. Pover, Clive D. Morris, Jean-Yves Douillard
01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
Juan W. Valle, Anne Armstrong, Chris Newman, Valery Alakhov, Grzegorz Pietrzynski, Julie Brewer, Sue Campbell, Pippa Corrie, Eric K. Rowinsky, Malcolm Ranson
01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
Srikala S. Sridhar, Eric Winquist, Andrea Eisen, Sebastien J. Hotte, Elaine McWhirter, Ian F. Tannock, Som D. Mukherjee, Lisa Wang, Chantale Blattler, John J. Wright, Malcolm J. Moore
01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Colin D. Weekes, Sujatha Nallapareddy, Michelle A. Rudek, Alexis Norris-Kirby, Daniel Laheru, Antonio Jimeno, Ross C. Donehower, Kathleen M. Murphy, Manuel Hidalgo, Sharyn D. Baker, Wells A. Messersmith
01.10.2011 | Phase II Studies | Ausgabe 5/2011
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness
Sung Yong Oh, Chi Young Jeong, Soon Chan Hong, Tae Hyo Kim, Chang Yoon Ha, Hyun Jin Kim, Gyeong-Won Lee, In Gyu Hwang, Joung Soon Jang, Hyuk-Chan Kwon, Jung Hun Kang
01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer
Sang Joon Shin, Jae Heon Jeong, Young Suk Park, Kyung Hee Lee, Byoung Yong Shim, Tae Won Kim, Do Youn Oh, Myung Ah Lee, Yong Tai Kim, Yeul Hong Kim, Dae Young Zang, Jae Kyung Roh, Joong Bae Ahn
